A Fund’s Exit: Haemonetics and the Illusion of Growth

by

Invenomic Capital Management has quietly liquidated its holdings in Haemonetics Corporation (HAE 0.54%), a transaction recorded in a recent SEC filing. The sum realized was $24.29 million, representing the complete disposal of 498,317 shares. It is a small act, perhaps, but one that deserves scrutiny, for it reveals more about the current climate than any grand pronouncement.

The fund’s withdrawal reduces its stake from 1.2% of its 13F portfolio to zero. The mechanics are simple enough, but the motivations, as always, are layered. The market, it seems, rewards enthusiasm, even when that enthusiasm is not entirely justified by underlying realities.

As of Friday’s close, Haemonetics shares traded at $58.58, a figure 9% below its value a year prior. This underperformance stands in stark contrast to the broader market’s ascent, a gain of roughly 16% over the same period. The numbers speak for themselves, though they are rarely heeded.

The Company in Brief

Metric Value
Revenue (TTM) $1.32 billion
Net Income (TTM) $175.44 million
Market Capitalization $2.74 billion
Price (as of Friday) $58.58

Haemonetics provides the apparatus for blood collection and transfusion – automated devices, software, and the disposables that keep them functioning. It serves hospitals, blood banks, and plasma centers, a sector reliant on efficiency and, increasingly, on cost-cutting. The company’s strategy is, on the surface, sensible: to deliver integrated solutions that improve both safety and productivity.

Current Portfolio Holdings

  • NASDAQ: VTRS: $69.64 million (3.4% of AUM)
  • NYSE: GPN: $61.73 million (3.0% of AUM)
  • NASDAQ: XRAY: $58.66 million (2.8% of AUM)
  • NASDAQ: AKAM: $58.59 million (2.8% of AUM)
  • NYSE: EGO: $53.75 million (2.6% of AUM)

The Meaning of the Transaction

The recent surge in Haemonetics’ share price – a near 70% leap last quarter – appears to have been the catalyst for Invenomic’s decision. Earnings exceeded expectations, prompting a temporary frenzy of buying. It is a pattern as old as the markets themselves: a brief moment of optimism followed by a return to sober assessment. Invenomic, it seems, chose to capitalize on the peak. A sensible move, perhaps, given the subsequent decline of 27% this year.

To be clear, Haemonetics is not a failing enterprise. It is, however, facing headwinds. Revenue dipped by 3% last quarter, despite growth in certain segments. The narrative has become more complex – divestitures, shifting product mixes, and uneven performance across business lines obscure what was once a straightforward growth story. The company is no longer a simple equation.

There is a paradox at play. Profitability is improving, with gross margins expanding and operating income climbing. The company is becoming more efficient even as top-line growth slows. This tension – between cost control and revenue generation – is likely a key factor in Invenomic’s decision. Haemonetics is no longer a pure growth play, nor is it yet a reliable source of stable returns. It occupies a precarious middle ground, a position that demands careful scrutiny.

The markets, it seems, prefer illusions. A rising tide lifts all boats, even those with leaks. Invenomic, at least, appears to have recognized the limitations of the current swell.

Read More

2026-03-21 00:52